IL15 and renal cell carcinoma: The first in-human clinical trial employing recombinant human IL-15 (rhIL-15) in patients with metastatic melanoma and renal cell cancer (RCC) showed that administration of IL-15 is safe and that can enhance the function and proliferation of NK cells in peripheral blood of cancer patients (53).